British Adendra Therapeutics closes $53m f...The 2021 spin out of London-based Francis Crick Institute is the very first UK company formation deal of life sciences investor ATP (Apple Tree Partners). more ➔
Recordati bags EUSA to strengthen rare dis...Italian pharma company Recordati is putting €750m on the table to acquire UK-based specialty pharmaceutical company EUSA Pharma. more ➔
Sanofi acquires therapeutic acne vaccineSanofi is strengthening its vaccine business by acquiring an Austrian company. The French pharma group is taking over skin disease specialist Origrimm Biotechnology. more ➔
US-Greek Venture gets €32m cash injectio...US cell & gene therapy manufacturer Orgenesis Inc. announced that its joint venture with Theracell Advanced Biotechnology SA has received €32m in funding by Enterprise Greece. more ➔
Early-stage ventures fighting AMR wanted!The start-up competition @AMR conference supported by INCATE has started. Early-stage ventures fighting drug resistant bacterial infections in the therapeutics or diagnostics area interested to be on … more ➔
Quell raises US$156m for Treg cell therapy...Quell Therapeutics has raised a whopping US$156m from a prestigious investor group in an oversubscribed Series B financing. With the funds, the British biotech wants to hasten its CAR-Treg cell therapy … more ➔
Vaccibody – now Nykode – in va...Vaccibody rebrands as Nykode Therapeutics and teams up with Regeneron in a vaccine deal potentially worth US$925m. more ➔
EC signs prepurchase agreement with Valnev...The European Commission has inked the pre-purchase agreement over Valnevas inactivated whole virus pandemic vaccine VLA2001 announed in mid-October. more ➔
Vifor buys out one-drug wonder SanifitSwiss Vifor Pharma is shelling out more than €375m for Mallorca-based Sanifit, a clinical-stage cardio-renal biopharmaceutical company with a single compound in development. more ➔
Novo Nordisk snatches DicernaNovo Nordisk announced today that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals for up to US$ 3.3bn, which is a surcharge of about 80%. more ➔
